CD28 costimulation promotes an antitumor CD8^(+) T cell response in myeloid antigen-presenting cell niches  

作　　者：Jacques A.Nunès Daniel Olive 

机构地区：[1]Team Immunity and Cancer,Centre de Recherche en Cancérologie de Marseille(CRCM),Inserm,U1068,CNRS,UMR7258,Institut Paoli-Calmettes,Aix-Marseille University,UM 105,Marseille,France [2]IBiSA Immunomonitoring Platform,CRCM,Institut Paoli-Calmettes,Marseille,France

出　　处：《Cellular & Molecular Immunology》2022年第2期147-149,共3页中国免疫学杂志（英文版）

基　　金：The team“Immunity and Cancer”was labeled by the Fondation pour la Recherche Médicale“Equipe FRM DEQ20180339209”.DO is Senior Scholar of the Institut Universitaire de France.

摘　　要：Ectopic lymphoid structures found within the tumor stroma,such as tertiary lymphoid structures(TLSs),are predictive markers of immune checkpoint blockade(ICB)in solid tumors.In a recent study in Cancer Cell,Duraiswamy et al.highlighted other immune structures,such as myeloid antigen-presenting cell(APC)niches,in the context of high-grade serous ovarian cancers(HGSOCs)[1].In these structures,programmed cell death receptor 1(PD-1)^(+)tumor-infiltrating T lymphocytes(TILs)undergo a full activation program(a license to kill)via the CD28 costimulatory molecule during PD-1 blockade in HGSOC.

关 键 词：stimulation MYELOID al. 

分 类 号：R73[医药卫生—肿瘤] R392[医药卫生—临床医学]